New kidney disease drug candidate tested in healthy people for first time in asia
NCT ID NCT07600450
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial will test a single dose of the experimental drug GSK4771261 in 30 healthy adults of Chinese, Japanese, and White/European backgrounds. The main goal is to check safety, how the body processes the drug, and whether it causes an immune response. No treatment benefit is expected, as this study is only about safety and drug behavior.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GSK4771261
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could your bone health decide if a dental implant lasts?
- Can a simple foot pump ease leg swelling in hospital patients?
- Could your blood type predict kidney treatment success?
- Can community hospitals in zambia master severe disease care?
- Can an ancient herbal remedy soothe the aftermath of stone surgery?
- AI coach may soothe the agony of Dialysis-Related itching